MedWatch

Bank sees increasing likelihood of third Novo Nordisk upgrade

In a new memo, Citi bank concludes that there is a good chance that Novo Nordisk will upgrade its financial guidance again in November, based on sales of obesity drug Wegovy.

Photo: Novo Nordisk / PR

US-based bank Citi assesses that it is increasingly likely that Novo Nordisk will upgrade its financial guidance for the third time this year in connection with its Q3 report, which will be released at the start of November.

The bank concluded this after a meeting with Novo's CFO, Karsten Munk Knudsen. Citi's "buy" recommendation with a target price of DKK 780 (USD 123) remains unchanged.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs